http://stdjhs.scienceandtechnology.com.vn/index.php/stdjhs <p><strong>The Science and Technology Development Journal - Health Sciences (STDJ-HS) (ISSN&nbsp;2734-9446)</strong> is an international, open access, and peer-reviewed journal published by School of Medicine, Vietnam National University Ho Chi Minh City. The journal publishes researches in the fields of medicine, pharmacy, dentistry, public health, traditional medicine, nursing, and medical technology. Relevant articles from other disciplines of health professions may be considered for publication. However, the journal places an emphasis on publishing high-quality, high-impact and novel research. Articles can be submitted in the in the form of original research articles, reviews, case reports, commentaries or letters to the editor. We accept manuscripts in both English and Vietnamese.</p> <p><span id="result_box" class="" lang="en"><span title="Tạp chí đã trải qua 20 năm phát triển và đã trở thành nhịp cầu giao lưu khoa học, cũng như làm phong phú tài liệu tham khảo cho đội ngũ giảng viên, nghiên cứu sinh, sinh viên ĐHQG-HCM nói riêng và các Trường đại">&nbsp;</span></span></p> <p>&nbsp;</p> <p><span class="" lang="en"><span title="Tạp chí đã trải qua 20 năm phát triển và đã trở thành nhịp cầu giao lưu khoa học, cũng như làm phong phú tài liệu tham khảo cho đội ngũ giảng viên, nghiên cứu sinh, sinh viên ĐHQG-HCM nói riêng và các Trường đại"><span id="result_box" class="" lang="en"><span title="Tạp chí Phát triển Khoa học và Công nghệ (PTKH&amp;CN) của Đại học Quốc gia thành phố Hồ Chí Minh (ĐHQG-HCM) được thành lập từ năm 1997, ra số đầu tiên vào tháng 1 năm 1998. Từ năm 2006 Tạp chí đã"><strong>Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal focusing on:</strong><br></span></span></span></span></p> <p>&nbsp;</p> <ul> <li class="show">Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.</li> <li class="show">Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.</li> </ul> <p><span class="" lang="en"><span title="• Khoa học Trái đất và Môi trường"><span id="result_box" class="" lang="en">&nbsp;</span></span></span></p> Viet Nam National University Ho Chi Minh City en-US Science and Technology Development Journal: Health Sciences 2734-9446 <p>Copyright The Author(s) 2018. This article is published with open access by Vietnam National University, Ho Chi Minh city, Vietnam. This article is distributed under the terms of the&nbsp;<a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noopener">Creative Commons Attribution License (CC-BY 4.0)</a> which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.&nbsp;</p> http://stdjhs.scienceandtechnology.com.vn/index.php/stdjhs/article/view/572 <p>Dravet syndrome is a developmental epileptic encephalopathy characterized by early onset drug-resistant seizures and other clinical features, including intellectual disability and impairments in behavior, motor, and sleep which cause poor quality of life and impact the long-term course. The pathogenesis of Dravet syndrome is strongly connected to the dysfunction of the voltage-gated sodium channel, more specifically, to mutations in SCN1A gene. Epilepsy in Dravet syndrome is very refractory and seizures remain poorly controlled even with multiple conventional anti-epileptic drugs. Therapeutic approaches in Dravet syndrome have undergone tremendous changes in the lastest years and the current consensus of seizure management strategy in Dravet syndrome consists of a combination of conventional drugs and three recently approved drugs including stiripentol, cannabidiol, and fenfluramine. This review article aims to update recent changes to the therapeutic landscape for Dravet syndrome by summarizing the most key data from the clinical development of stiripentol, cannabidiol, and fenfluramine. This article also reviews and discusses the latest findings of other pharmacotherapies in development, including serotonergic agents, soticlestat, verapamil as well well strategies to treat the underlying cause of Dravet syndrome, including gene therapy and antisense oligonucleotides.</p> Hang Thi Thu Do ##submission.copyrightStatement## http://creativecommons.org/licenses/by/4.0 2024-03-10 2024-03-10 2024 Online First press press 10.32508/stdjhs.v4i2.572 title description none g